BXMPY (Beximco Pharmaceuticals) Cyclically Adjusted Revenue per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share?

Beximco Pharmaceuticals BXMPY 93 Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $0.248. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beximco Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beximco Pharmaceuticals was 17.80% per year. The lowest was 13.70% per year. And the median was 17.40% per year.

As of today (2026-07-16), Beximco Pharmaceuticals's current stock price is $0.00. Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.00. Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Beximco Pharmaceuticals  (OTCPK:BXMPY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BXMPY vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.248/330.2130*330.2130
=0.248

Current CPI (Mar. 2026) = 330.2130.

Beximco Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.072 241.428 0.098
201612 0.070 241.432 0.096
201703 0.069 243.801 0.093
201706 0.074 244.955 0.100
201709 0.078 246.819 0.104
201712 0.079 246.524 0.106
201803 0.077 249.554 0.102
201806 0.088 251.989 0.115
201809 0.098 252.439 0.128
201812 0.104 251.233 0.137
201903 0.105 254.202 0.136
201906 0.108 256.143 0.139
201909 0.104 256.759 0.134
201912 0.113 256.974 0.145
202003 0.120 258.115 0.154
202006 0.118 257.797 0.151
202009 0.126 260.280 0.160
202012 0.136 260.474 0.172
202103 0.134 264.877 0.167
202106 0.141 271.696 0.171
202109 0.154 274.310 0.185
202112 0.155 278.802 0.184
202203 0.163 287.504 0.187
202206 0.159 296.311 0.177
202209 0.178 296.808 0.198
202212 0.180 296.797 0.200
202303 0.174 301.836 0.190
202306 0.182 305.109 0.197
202309 0.203 307.789 0.218
202312 0.198 306.746 0.213
202403 0.200 312.332 0.211
202406 0.206 314.175 0.217
202409 0.213 315.301 0.223
202412 0.224 315.605 0.234
202503 0.229 319.799 0.236
202506 0.227 322.561 0.232
202509 0.251 324.800 0.255
202512 0.255 324.054 0.260
202603 0.248 330.213 0.248

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Beximco Pharmaceuticals (BXMPY) has a Cyclically Adjusted Revenue per Share of $0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Beximco Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.